Benefits of Covalescent Plasma Therapy in COVID-19 Infection
DOI:
https://doi.org/10.53089/medula.v10i2.76Keywords:
Convalescent plasma therapy, COVID-19, infectious diseaseAbstract
The pandemic of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has attracted the world’s attention. On June the cases spreaded more than 200 countries and territories. America occupied the highest level of confirmed cases 4.437.946 and fatality cases 119.761. In Indonesia has 47.898 confirmed cases and 2.535 fatality cases. Until now there are no specific drugs or vaccines available to treat COVID-19. The principle therapy in Indonesia are oxygen supplementation, fluid theraphy, vasopressor drugs, empiric antibiotic, symptomatic therapy, and systemic corticosteroid. The Food and Drug Administration (FDA) recommends therapy in patients COVID-19 are use convalescent plasma taken from patients who recovered from infection. Convalescent plasma therapy is the administration of passive polyclonal antibodies (Ab) to provide immediate immunity that has been used more than a century ago. Several studies have reported that the use of convalescent plasma increases patient survival, improves clinical symptoms, decreases mortality and there are no significant adverse effects.
References
Jin Y-H, Cai L, Cheng Z-S, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7(4):69-70.doi:10.4038/jmj.v31i2.72
Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;117(17):9490-9496. doi:10.1073/pnas.2004168117
Susilo A, Rumende CM, Pitoyo CW, et al. Coronavirus Disease 2019 : Tinjauan Literatur Terkini Coronavirus Disease 2019 : Review of Current Literatures. J Penyakit Dalam Indones. 2020;7(1):45-67.
Salazar E, Perez KK, Ashraf M, et al. Treatment of COVID-19 Patients with Convalescent Plasma. Am J Pathol. Published online 2020.
World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 70. Published 2019. Accessed June 24, 2020.https://www.who.int/emergencies/diseases/novel-coronavirus 2019?gclid=CjwKCAjw88v3BRBFEiwApwLevRLLA2KTssIhUnxlrfWnjHDDNdyXMyOSfizDcXmMqmhfeLVgfgJzRoCj1MQAvD_BwE
Gugus Tugas Percepatan Penanganan Covid-19. Published online 2020. doi:covid19.go.id
Fauci AS, Lane HC, Redfield RR. Covid-19 - Navigating the uncharted. N Engl J Med. 2020;382(13):1268-1269. doi:10.1056/NEJMe2002387
Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma. JAMA - J Am Med Assoc. 2020;323(16):1582-1589. doi:10.1001/jama.2020.4783
Keith P, Day M, Perkins L, Moyer L, Hewitt K, Wells A. A novel treatment approach to the novel coronavirus : an argument for the use of therapeutic plasma exchange for fulminant. 2020;24(128):1-3.
Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. J Chem Inf Model. 2019;53(9):1689-1699. doi:10.1017/CBO9781107415324.004
Hung IFN, To KKW, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52(4):447-456. doi:10.1093/cid/ciq106
Rojas M, Rodríguez Y, Monsalve DM, et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun Rev. 2020;19(7):102554. doi:10.1016/j.autrev.2020.102554
Sullivan HC, Roback JD. Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic. Chest. 2020;(January):1-4.
Food and Drug Administration. Recommendations for Investigational COVID‐19 Convalescent Plasma. Published2020.https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma#Collection of COVID-19
Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl). 2020;133(9):1015-1024. doi:10.1097/CM9.0000000000000722
Zheng M, Song L. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV. Cell Mol Immunol. 2020;17(5):536-538. doi:10.1038/s41423-020-0385-z
Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-574. doi:10.1016/S0140-6736(20)30251-8
Ye M, Fu D, Ren Y, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. Published online 2020:0-1. doi:10.1002/jmv.25882
Lian J, Jin X, Hao S, et al. Analysis of Epidemiological and Clinical Features in Older Patients With Coronavirus Disease 2019 ( COVID-19 ) Outside Wuhan. Oxford Univ Press Infect Dis Soc Am. Published online 2020:1-8. doi:10.1093/cid/ciaa242
Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514-523.
Kakodkar P, Kaka N, Baig M. A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19). Cureus. 2020;12(4):1-18. doi:10.7759/cureus.7560
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513. doi:10.1016/S0140-6736(20)30211-7
Zhang B, Liu S, Tan T, et al. Treatment With Convalescent Plasma for Critically Ill Patients With SARS -CoV-2 Infection. 2020;(January).
Burhan E, Isbaniah F, Susanto AD, et al. Pneumonia COVID-19 Diagnosis Dan Penatalaksanaan Di Indonesia.; 2020. doi:10.1331/JAPhA.2015.14093
Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80-90. doi:10.1093/infdis/jiu396
Ahn JY, Sohn Y, Lee SH, et al. Use of convalescent plasma therapy in two covid-19 patients with acute respiratory distress syndrome in Korea. J Korean Med Sci. 2020;35(14):2-9. doi:10.3346/JKMS.2020.35.E149
Marano G, Vaglio S, Pupella S, et al. Convalescent plasma: New evidence for an old therapeutic tool? Blood Transfus. 2016;14(2):152-157. doi:10.2450/2015.0131-15
Edwards T, Semple MG, De Weggheleire A, et al. Design and analysis considerations in the Ebola-Tx trial evaluating convalescent plasma in the treatment of Ebola virus disease in Guinea during the 2014-2015 outbreak. Clin Trials. 2016;13(1):13-21. doi:10.1177/1740774515621056
Rajendran K, Narayanasamy K, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol. Published online 2020:1-9. doi:10.1002/jmv.25961
Sahu KK, Jindal V, Siddiqui AD, Cerny J, Gerber JM. Convalescent Plasma Therapy: A Passive Therapy for An Aggressive COVID-19. J Med Virol. Published online 2020. doi:10.1002/jmv.26047
Chary MA, Barbuto AF, Izadmehr S, Hayes BD, Burns MM. COVID-19: Therapeutics and Their Toxicities. J Med Toxicol. 2020;(April). doi:10.1007/s13181-020-00777-5
Chun S, Chung CR, Ha YE, et al. Possible Transfusion-Related Acute Lung Injury Following Convalescent Plasma Transfusion in a Patient With Middle East Respiratory Syndrome. Published online 2016:393-395.
Seghatchian J, Lanza F. Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both donors and recipients alike. Elsevier. 2020;(January).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 MEDULA
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
